28.34
0.25%
-0.07
After Hours:
28.34
Integra Lifesciences Holdings Corp stock is currently priced at $28.34, with a 24-hour trading volume of 444.07K.
It has seen a -0.25% decreased in the last 24 hours and a -16.03% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $28.29 pivot point. If it approaches the $29.39 resistance level, significant changes may occur.
Previous Close:
$28.41
Open:
$28.42
24h Volume:
444.07K
Market Cap:
$2.23B
Revenue:
$1.54B
Net Income/Loss:
$67.74M
P/E Ratio:
23.42
EPS:
1.21
Net Cash Flow:
$73.09M
1W Performance:
-1.19%
1M Performance:
-16.03%
6M Performance:
-20.24%
1Y Performance:
-47.71%
Integra Lifesciences Holdings Corp Stock (IART) Company Profile
Name
Integra Lifesciences Holdings Corp
Sector
Industry
Phone
609-275-0500
Address
311 Enterprise Drive, Plainsboro, NJ
Integra Lifesciences Holdings Corp Stock (IART) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-05-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Nov-14-23 | Initiated | CL King | Buy |
Aug-24-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jul-12-23 | Upgrade | Jefferies | Hold → Buy |
Jun-08-23 | Downgrade | Argus | Buy → Hold |
May-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
May-23-23 | Downgrade | Citigroup | Neutral → Sell |
Oct-12-22 | Initiated | Jefferies | Hold |
Jul-25-22 | Initiated | Morgan Stanley | Equal-Weight |
Apr-13-22 | Downgrade | Truist | Buy → Hold |
Dec-17-21 | Upgrade | JP Morgan | Underweight → Neutral |
Sep-15-21 | Downgrade | BTIG Research | Buy → Neutral |
Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
May-27-20 | Initiated | Citigroup | Neutral |
Apr-03-20 | Initiated | SunTrust | Buy |
Jan-07-20 | Downgrade | Piper Jaffray | Overweight → Neutral |
Jan-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-03-19 | Initiated | SunTrust | Buy |
Nov-28-18 | Initiated | UBS | Neutral |
Aug-07-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jul-26-18 | Upgrade | BTIG Research | Neutral → Buy |
Jul-02-18 | Downgrade | Citigroup | Buy → Neutral |
Jan-05-18 | Resumed | Cantor Fitzgerald | Neutral |
Jan-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
Nov-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
Oct-30-17 | Downgrade | Wells Fargo | Outperform → Market Perform |
Oct-27-17 | Downgrade | JP Morgan | Overweight → Neutral |
Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
May-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
Jan-13-17 | Reiterated | RBC Capital Mkts | Sector Perform |
Jan-06-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
Dec-12-16 | Initiated | UBS | Buy |
View All
Integra Lifesciences Holdings Corp Stock (IART) Latest News
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024
GlobeNewswire Inc.
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks Investment Research
Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline
Zacks Investment Research
Here's Why Investors Should Retain Integra (IART) Stock Now
Zacks Investment Research
Integra LifeSciences Completes the Acquisition of Acclarent, Inc.
GlobeNewswire Inc.
Why Is Integra (IART) Down 4% Since Last Earnings Report?
Zacks Investment Research
Integra Lifesciences Holdings Corp Stock (IART) Financials Data
Integra Lifesciences Holdings Corp (IART) Revenue 2024
IART reported a revenue (TTM) of $1.54 billion for the quarter ending December 31, 2023, a -1.03% decline year-over-year.
Integra Lifesciences Holdings Corp (IART) Net Income 2024
IART net income (TTM) was $67.74 million for the quarter ending December 31, 2023, a -62.48% decrease year-over-year.
Integra Lifesciences Holdings Corp (IART) Cash Flow 2024
IART recorded a free cash flow (TTM) of $73.09 million for the quarter ending December 31, 2023, a -66.38% decrease year-over-year.
Integra Lifesciences Holdings Corp (IART) Earnings per Share 2024
IART earnings per share (TTM) was $0.83 for the quarter ending December 31, 2023, a -61.57% decline year-over-year.
About Integra Lifesciences Holdings Corp
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
Cap:
|
Volume (24h):